Clinical trials of disease-modifying agents in pediatric MS

Objective The impetus for this consensus discussion was to recommend clinical trial designs that can deliver high-quality data for effective therapies for pediatric patients, in a reasonable timeframe, with a key focus on short- and long-term safety. Methods The International Pediatric Multiple Sclerosis Study Group convened a meeting of experts to review the advances in the understanding of pediatric-onset multiple sclerosis (MS) and the advent of clinical trials for this population. Results In the last few years, convincing evidence has emerged that the biological processes involved in MS are largely shared across the age span. As such, treatments proven efficacious for the care of adults with MS have a biological rationale for use in pediatric MS given the relapsing-remitting course at onset and high relapse frequency. There are also ethical considerations on conducting clinical trials in this age group including the use of placebo owing to highly active disease. It is imperative to reconsider study design and implementation based on what information is needed. Are studies needed for efficacy or should safety be the primary goal? Further, there have been major recruitment challenges in recently completed and ongoing pediatric MS trials. Phase 3 trials for every newly approved therapy for adult MS in the pediatric MS population are simply not feasible. Conclusions A primary goal is to ensure high-quality evidence-based treatment for children and adolescents with MS, which will improve our understanding of the safety of these agents and remove regulatory or insurance-based limitations in access to treatment.

[1]  V. Rivera,et al.  Current Advances in Pediatric Onset Multiple Sclerosis , 2020, Biomedicines.

[2]  D. Neubauer,et al.  Too Many Avoidable Suicides Occur Worldwide in Young Patients , 2019, Rambam Maimonides medical journal.

[3]  E. Waubant,et al.  Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US , 2018, Neurology.

[4]  K. Deiva,et al.  Clinical trials in pediatric multiple sclerosis : a British-French patient and parent perspective , 2018 .

[5]  D. Arnold,et al.  Trial of Fingolimod versus Interferon Beta‐1a in Pediatric Multiple Sclerosis , 2018, The New England journal of medicine.

[6]  L. Krupp,et al.  Cognitive impairment in pediatric-onset multiple sclerosis is detected by the Brief International Cognitive Assessment for Multiple Sclerosis and computerized cognitive testing , 2018, Multiple sclerosis.

[7]  R. Alroughani,et al.  Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS). , 2018, Pediatric neurology.

[8]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[9]  P. Walson,et al.  Do Paediatric Investigation Plans (PIPs) Advance Paediatric Healthcare? , 2017, Pediatric Drugs.

[10]  G. Holmes,et al.  Extrapolating evidence of antiepileptic drug efficacy in adults to children ≥2 years of age with focal seizures: The case for disease similarity , 2017, Epilepsia.

[11]  R. Alroughani,et al.  The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study. , 2017, Pediatric neurology.

[12]  E. Waubant,et al.  Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS , 2017, Neurology.

[13]  B. Banwell,et al.  The computer-based Symbol Digit Modalities Test: establishing age-expected performance in healthy controls and evaluation of pediatric MS patients , 2017, Neurological Sciences.

[14]  W. Chin,et al.  Moving toward a paradigm shift in the regulatory requirements for pediatric medicines , 2016, European Journal of Pediatrics.

[15]  A. Ghezzi,et al.  Pediatric multiple sclerosis , 2016, Neurology.

[16]  A. Ponsonby,et al.  Environmental and genetic factors in pediatric inflammatory demyelinating diseases , 2016, Neurology.

[17]  L. Krupp,et al.  Pediatric multiple sclerosis , 2016, Neurology.

[18]  T. Müller,et al.  Children with multiple sclerosis should not become therapeutic hostages , 2016, Therapeutic advances in neurological disorders.

[19]  Cody S. Olsen,et al.  Characteristics of Children and Adolescents With Multiple Sclerosis , 2016, Pediatrics.

[20]  Division Neurology Products FDA Update: Anti-epileptic drug efficacy in adults can be extrapolated to pediatric patients , 2016 .

[21]  M. Filippi,et al.  Natalizumab in the pediatric MS population: results of the Italian registry , 2015, BMC Neurology.

[22]  P. Huppke,et al.  Extensive acute axonal damage in pediatric multiple sclerosis lesions , 2015, Annals of neurology.

[23]  L. Krupp,et al.  The Symbol Digit Modalities Test is an effective cognitive screen in pediatric onset multiple sclerosis (MS) , 2014, Journal of the Neurological Sciences.

[24]  B. Healy,et al.  Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. , 2014, Multiple sclerosis and related disorders.

[25]  D. Arnold,et al.  Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials , 2013, Neurology.

[26]  M. Sormani,et al.  MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials , 2013, The Lancet Neurology.

[27]  A. Ghezzi,et al.  Subcutaneous Interferon Beta-1a in Pediatric Multiple Sclerosis , 2013, Journal of child neurology.

[28]  A. Ghezzi,et al.  International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions , 2013, Multiple sclerosis.

[29]  N. Stefano,et al.  Time to first relapse as an endpoint in multiple sclerosis clinical trials , 2013, Multiple sclerosis.

[30]  D. Prayer,et al.  Natalizumab therapy for highly active pediatric multiple sclerosis. , 2013, JAMA neurology.

[31]  A. Bar-Or,et al.  International Pediatric MS Study Group Clinical Trials Summit , 2013, Neurology.

[32]  E. Waubant,et al.  Cognitive Impairment Occurs in Children and Adolescents With Multiple Sclerosis , 2013, Journal of child neurology.

[33]  A. Ghezzi,et al.  Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis , 2012, Multiple sclerosis.

[34]  D. Arnold,et al.  MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study , 2011, The Lancet Neurology.

[35]  E. Waubant,et al.  Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children , 2011, Neurology.

[36]  Daniela Pohl,et al.  Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study , 2011, The Lancet Neurology.

[37]  M. Wintermark,et al.  Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. , 2009, Archives of neurology.

[38]  Luca Roccatagliata,et al.  Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta‐analytic approach , 2009, Annals of neurology.

[39]  Amit Bar-Or,et al.  Lesion distribution in children with clinically isolated syndromes , 2008, Annals of neurology.

[40]  P. Vermersch,et al.  Natural history of multiple sclerosis with childhood onset. , 2007, The New England journal of medicine.

[41]  M. Freedman,et al.  Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis , 2006, Neurology.

[42]  P. Vermersch,et al.  Interferon-β treatment in patients with childhood-onset multiple sclerosis ☆ , 2001 .

[43]  E. Waubant,et al.  Interferon Beta-1a in Children with Multiple Sclerosis is Well Tolerated , 2001, Neuropediatrics.

[44]  L. Ramió-Torrentá,et al.  Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis. , 2013, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[45]  B. Healy,et al.  Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. , 2009, Archives of neurology.

[46]  D. Berry Bayesian clinical trials , 2006, Nature Reviews Drug Discovery.

[47]  P. Vermersch,et al.  Interferon-beta treatment in patients with childhood-onset multiple sclerosis. , 2001, The Journal of pediatrics.

[48]  A. Ghezzi,et al.  Pediatric multiple sclerosis Clinical features and outcome , 2022 .